|
rs113488022
|
|
Thyroid Nodule
|
|
0.100 |
GeneticVariation
|
BEFREE |
Testing for BRAF (V600E) Mutation in Thyroid Nodules with Fine-Needle Aspiration (FNA) Read as Suspicious for Malignancy (Bethesda V, Thy4, TIR4): a Systematic Review and Meta-analysis.
|
31811566 |
2020 |
|
rs113488022
|
|
Thyroid Nodule
|
|
0.100 |
GeneticVariation
|
BEFREE |
Evaluation of BRAF V600E mutation status combined with cytomorphological features for diagnosis of PTC in cytologically indeterminate thyroid nodules can significantly improve diagnostic accuracy and reduce the number of diagnostic operations (calculator available at www.ptc-calc.we2host.lt).
|
29566402 |
2019 |
|
rs113488022
|
|
Thyroid Nodule
|
|
0.100 |
GeneticVariation
|
BEFREE |
The preoperative knowledge of the V600E mutation status is fundamental to plan total thyroidectomy with certainty and should be part of the decision tree for the management of thyroid nodules.
|
26854757 |
2016 |
|
rs113488022
|
|
Thyroid Nodule
|
|
0.100 |
GeneticVariation
|
BEFREE |
Initial clinical experience with BRAF(V600E) mutation analysis of core-needle biopsy specimens from thyroid nodules.
|
26215382 |
2016 |
|
rs113488022
|
|
Thyroid Nodule
|
|
0.100 |
GeneticVariation
|
BEFREE |
Of the 56 previous AUS result thyroid nodules with surgical management, BRAF(V600E) mu</span>tation analysis led to therapeutic surgery in 5.4% by decreasing unnecessary diagnostic surgery.
|
25978151 |
2015 |
|
rs113488022
|
|
Thyroid Nodule
|
|
0.100 |
GeneticVariation
|
BEFREE |
The probability of PTC for thyroid nodules with intermediat</span>e-risk (IR) US and atypia of undetermined significance/follicular lesion of undetermined significance (AUS/FLUS) FNAB was significantly dependent on BRAF V600E mutation status based on our prediction table (negative, 29.2% vs positive, 87.5%; P < 0.001).
|
26020381 |
2015 |
|
rs113488022
|
|
Thyroid Nodule
|
|
0.100 |
GeneticVariation
|
BEFREE |
In the management of thyroid nodules with benign cytology but positive BRAF(V600E) mutation, thyroidectomy should be considered in nodules which have 2 or more suspicious US features and are considered discordant on image-cytology correlation.
|
25616949 |
2015 |
|
rs113488022
|
|
Thyroid Nodule
|
|
0.100 |
GeneticVariation
|
BEFREE |
Evaluation of the Real-Q BRAF V600E Detection Assay in Fine-Needle Aspiration Samples of Thyroid Nodules.
|
25937618 |
2015 |
|
rs113488022
|
|
Thyroid Nodule
|
|
0.100 |
GeneticVariation
|
BEFREE |
For thyroid nodules that were diagnosed cytologically as suspicious for papillary thyroid cancer, univariate pooled sensitivity using FNA and BRAF(V600E) results was 52% (95% confidence interval, 39%-64%).
|
26232865 |
2015 |
|
rs113488022
|
|
Thyroid Nodule
|
|
0.100 |
GeneticVariation
|
BEFREE |
Value of TIRADS, BSRTC and FNA-BRAF V600E mutation analysis in differentiating high-risk thyroid nodules.
|
26597052 |
2015 |
|
rs113488022
|
|
Thyroid Nodule
|
|
0.100 |
GeneticVariation
|
BEFREE |
BRAF V600E detection is currently used as molecular test to improve the diagnosis of thyroid nodules, yet it lacks sensitivity.
|
26581891 |
2015 |
|
rs113488022
|
|
Thyroid Nodule
|
|
0.100 |
GeneticVariation
|
BEFREE |
Evaluation of the Anyplex BRAF V600E real-time detection assay using dual-priming oligonucleotide technology in fine-needle aspirates of thyroid nodules.
|
26354351 |
2015 |
|
rs113488022
|
|
Thyroid Nodule
|
|
0.100 |
GeneticVariation
|
BEFREE |
The aim of the study was to determine BRAF T1799A mutation and KRas proto-oncogene mutation, and the analysis of RASSF1A promoter methylation level in cytological material obtained from FNAB specimens of thyroid nodules.
|
26457492 |
2015 |
|
rs113488022
|
|
Thyroid Nodule
|
|
0.100 |
GeneticVariation
|
BEFREE |
These results indicate that BRAF(V600E) assessment by pyrosequencing is a reliable assay useful to refine inconclusive cytology of thyroid nodules also in the presence of concurrent HT.
|
23775008 |
2014 |
|
rs113488022
|
|
Thyroid Nodule
|
|
0.100 |
GeneticVariation
|
BEFREE |
Diagnostic value of B-RAF(V600E) in difficult-to-diagnose thyroid nodules using fine-needle aspiration: systematic review and meta-analysis.
|
24167125 |
2014 |
|
rs113488022
|
|
Thyroid Nodule
|
|
0.100 |
GeneticVariation
|
BEFREE |
One hundred and fifty-three thyroid samples obtained by FNA of thyroid nodules from 151 patients were subjected to the analysis of BRAF V600E mutation by direct sequencing.
|
25194426 |
2014 |
|
rs113488022
|
|
Thyroid Nodule
|
|
0.100 |
GeneticVariation
|
BEFREE |
The detection rate of the BRAF(V600E) mutation in thyroid nodules without suspicious US features was only 6.6 % (32/485).
|
24452872 |
2014 |
|
rs113488022
|
|
Thyroid Nodule
|
|
0.100 |
GeneticVariation
|
BEFREE |
We found TERT promoter mutations in 0.0% (0/179) of benign thyroid nodules and 7.0% (9/129) of thyroid nodules of differentiated thyroid cancer, representing a 100% diagnostic specificity and 7.0% sensitivity, with the latter rising to 38.0% (49/129) when combined with BRAF V600E testing.
|
25121551 |
2014 |
|
rs113488022
|
|
Thyroid Nodule
|
|
0.100 |
GeneticVariation
|
BEFREE |
BRAF V600E mutation, common in papillary thyroid carcinoma (PTC), is helpful in fine needle aspiration diagnosis of thyroid nodules and is being evaluated for targeted therapies.
|
24746198 |
2014 |
|
rs113488022
|
|
Thyroid Nodule
|
|
0.100 |
GeneticVariation
|
BEFREE |
We recommend that patients with a thyroid nodule with any suspicious sonographic feature undergo preoperative BRAF(V600E) testing for risk stratification and to guide the initial surgical approach in PTC.
|
25337709 |
2014 |
|
rs113488022
|
|
Thyroid Nodule
|
|
0.100 |
GeneticVariation
|
BEFREE |
Using pyrosequencing and quantitative methylation-specific PCR (Q-MSP) methods, FNABs from 79 and 38 patients with thyroid nodules in training and test groups, respectively, were analyzed for BRAF(V600E) mutation and gene methylation.
|
24588959 |
2014 |
|
rs113488022
|
|
Thyroid Nodule
|
|
0.100 |
GeneticVariation
|
BEFREE |
Detection of BRAF(V600E) in cytology specimens by pyrosequencing is a useful diagnostic adjunctive tool in the evaluation of thyroid nodules also in elderly subjects.
|
24267957 |
2013 |
|
rs113488022
|
|
Thyroid Nodule
|
|
0.100 |
GeneticVariation
|
BEFREE |
Diagnostic molecular markers, such as RET-PTC, RAS, and BRAF(V600E) mutations; galectin 3; and a new gene expression classifier, are outstanding examples that have improved diagnosis of thyroid nodules.
|
23668556 |
2013 |
|
rs113488022
|
|
Thyroid Nodule
|
|
0.100 |
GeneticVariation
|
BEFREE |
Does addition of BRAF V600E mutation testing modify sensitivity or specificity of the Afirma Gene Expression Classifier in cytologically indeterminate thyroid nodules?
|
23476074 |
2013 |
|
rs113488022
|
|
Thyroid Nodule
|
|
0.100 |
GeneticVariation
|
BEFREE |
The molecular tests on the thyroid nodule revealed the presence of BRAF-V600E mutation, but wild type BRAF in the ectopic tissue.
|
23200790 |
2013 |